103 related articles for article (PubMed ID: 8891429)
1. Laboratory probing of oncogenes from human liquid and solid specimens as markers of exposure to toxicants.
Nelson E
Crit Rev Toxicol; 1996 Sep; 26(5):483-549. PubMed ID: 8891429
[TBL] [Abstract][Full Text] [Related]
2. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of potential oncogene alterations in the ENU1564 rat mammary tumor model.
Hal DG; Stoica G
Anticancer Res; 1994; 14(2A):481-7. PubMed ID: 7912494
[TBL] [Abstract][Full Text] [Related]
4. P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis.
Chang KW; Sarraj S; Lin SC; Tsai PI; Solt D
Carcinogenesis; 2000 Jul; 21(7):1441-51. PubMed ID: 10874024
[TBL] [Abstract][Full Text] [Related]
5. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review.
Minamoto T; Mai M; Ronai Z
Cancer Detect Prev; 2000; 24(1):1-12. PubMed ID: 10757118
[TBL] [Abstract][Full Text] [Related]
6. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
Slebos RJ; Hoppin JA; Tolbert PE; Holly EA; Brock JW; Zhang RH; Bracci PM; Foley J; Stockton P; McGregor LM; Flake GP; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1223-32. PubMed ID: 11097231
[TBL] [Abstract][Full Text] [Related]
7. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
9. K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines.
Erill N; Cuatrecasas M; Sancho FJ; Farré A; Pour PM; Lluís F; Capellá G
Am J Pathol; 1996 Oct; 149(4):1333-9. PubMed ID: 8863680
[TBL] [Abstract][Full Text] [Related]
10. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
11. Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene.
Cerutti P; Hussain P; Pourzand C; Aguilar F
Cancer Res; 1994 Apr; 54(7 Suppl):1934s-1938s. PubMed ID: 7907948
[TBL] [Abstract][Full Text] [Related]
12. Assessment of K-ras, Smad4 and p53 gene alterations in colorectal metastases and their role in the metastatic process.
Losi L; Luppi G; Benhattar J
Oncol Rep; 2004 Dec; 12(6):1221-5. PubMed ID: 15547741
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations in chronic pancreatitis: evidence for early occurrence of p53 but not K-ras mutations.
Gansauge S; Schmid RM; Muller J; Adler G; Mattfeldt T; Beger HG
Br J Surg; 1998 Mar; 85(3):337-40. PubMed ID: 9529487
[TBL] [Abstract][Full Text] [Related]
14. Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor.
Hrasćan R; Pavelić K; Pavicić D; Krizanac S; Stajcer-Sittić V; Pecur L; Spaventi S; Klimpfinger M; Pavelić J
Anticancer Res; 1996; 16(6B):3761-6. PubMed ID: 9042254
[TBL] [Abstract][Full Text] [Related]
15. The evidence for human tumor suppressor genes.
Stanbridge EJ
Princess Takamatsu Symp; 1989; 20():3-13. PubMed ID: 2577336
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
Lehman TA; Bennett WP; Metcalf RA; Welsh JA; Ecker J; Modali RV; Ullrich S; Romano JW; Appella E; Testa JR
Cancer Res; 1991 Aug; 51(15):4090-6. PubMed ID: 1855224
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
18. ras and human tumors.
Rodenhuis S
Semin Cancer Biol; 1992 Aug; 3(4):241-7. PubMed ID: 1421168
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
[TBL] [Abstract][Full Text] [Related]
20. [Molecular study on minute alterations of the p53 and the N-ras genes in hematologic malignancies].
Kurosawa M
Hokkaido Igaku Zasshi; 1994 May; 69(3):543-54. PubMed ID: 7927179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]